HIV molecular immunology database

 

Search Antibody Database

Found 6 matching records:

Displaying record number 487

Download this epitope record as JSON.

MAb ID 0.5β (0.5 beta, 0.5beta)
HXB2 Location gp160(311-324)
DNA(7155..7196)
gp160 Epitope Map
Author Location gp120(316-330 HXB2)
Research Contact Shuzo Matsushita or Toshio Hattori of Kumamoto University
Epitope RGPGRAFVTIGKIG Epitope Alignment
RGPGRAFVTIGKIG epitope logo
Subtype B
Ab Type gp120 V3 // V3 glycan (V3g)
Neutralizing L (IIIB)
Species (Isotype) mouse(IgG1κ)
Patient  
Immunogen vaccine
Keywords anti-idiotype, antibody binding site, antibody generation, antibody interactions, binding affinity, brain/CSF, co-receptor, complement, enhancing activity, escape, mimics, neutralization, review, structure, variant cross-reactivity

Vaccine Details

Vaccine type protein
Vaccine strain B clade IIIB
Vaccine component Env

Notes

Showing 42 of 42 notes.

References

Showing 45 of 45 references.

Isolation Paper
Matsushita1988 S. Matsushita, M. Rober-Guroff, J. Rusche, A. Koito, T. Hattori, H. Hoshino, K. Javaherian, K. Takatsuki, and S. Putney. Characterization of a Human Immunodeficiency Virus neutralizing monoclonal antibody and mapping the neutralizing epitope. J. Virol., 62:2107-2114, 1988. PubMed ID: 2452899. Show all entries for this paper.

Boudet1994 F. Boudet, J. Theze, and M. Zouali. Anti-Idiotypic Antibodies to the Third Variable Domain of gp120 Induce an Anti-HIV-1 Antibody Response in Mice. Virology, 200:176-188, 1994. PubMed ID: 7510435. Show all entries for this paper.

Broder1994 C.C. Broder, P.L. Earl, D. Long, S.T. Abedon, B. Moss, and R.W. Doms. Antigenic implications of human immunodeficiency virus type 1 envelope quaternary structure: Oligomer-specific and -sensitive monoclonal antibodies. Proc. Natl. Acad. Sci. U.S.A., 91:11699-11703, 1994. 35 anti-gp41 and 27 anti-gp120 murine MAbs generated by immunization with oligomeric HIV-1 IIIB envelope were studied. These MAbs tended to react with conformational epitopes. 21 of the anti-gp41 MAbs reacted preferentially with oligomeric env, while only 1 of the anti-gp120 MAbs reacted more strongly with the oligomer, and 14 of the anti-gp120 preferentially recognized monomeric env. PubMed ID: 7972127. Show all entries for this paper.

Cook1994 D. G. Cook, J. Fantini, S. L. Spitalnik, and F. Gonzalez-Scarano. Binding of Human Immunodeficiency Virus Type 1 HIV-1 gp120 to Galactosylceramide (GalCer): Relationship to the V3 Loop. Virol., 201:206-214, 1994. Antibodies against GalCer can block infection of CD4-negative cells from the brain and colon that are susceptible to HIV infection. This paper explores the ability of a panel of MAbs to inhibit binding of gp120 to GalCer, and also of the binding of GalCer to inhibit MAb-gp120 interaction. MAbs to the V3 loop and GalCer showed mutual inhibition of binding to gp120, and anti-CD4 binding site MAbs showed reduced inhibition. N- and C-terminal MAbs didn't influence GalCer binding. PubMed ID: 8184533. Show all entries for this paper.

DSouza1991 M. P. D'Souza, P. Durda, C. V. Hanson, G. Milman, and Collaborating Investigators. Evaluation of Monoclonal Antibodies to HIV-1 by Neutralization and Serological Assays: An International Collaboration. AIDS, 5:1061-1070, 1991. PubMed ID: 1718320. Show all entries for this paper.

Emini1992 E. A. Emini, W. A. Schleif, J. H. Nunberg, A. J. Conley, Y. Eda, S. Tokiyoshi, S. D. Putney, S. Matsushita, K. E. Cobb, C. M. Jett, J. W. Eichberg, and K. K. Murthy. Prevention of HIV-1 Infection in Chimpanzees by gp120 V3 Domain-Specific Monoclonal Antibody. Nature, 355:728-730, 1992. PubMed ID: 1741059. Show all entries for this paper.

Faiman1996 Gabriel A. Faiman, Rena Levy, Jacob Anglister, and Amnon Horovitz. Contribution of Arginine Residues in the RP135 Peptide Derived from the V3 Loop of gp120 to Its Interaction with the Fv Fragment of the 0.5beta HIV-1 Neutralizing Antibody. J. Biol. Chem., 271(23):13829-13833, 7 Jun 1996. PubMed ID: 8662780. Show all entries for this paper.

Faiman1997 G. A. Faiman and A. Horovitz. Thermodynamic Analysis of the Interaction between the 0.5beta Fv Fragment and the RP135 Peptide Antigen Derived from the V3 Loop of HIV-1 gp120. J. Biol. Chem., 272:31407-31411, 1997. PubMed ID: 9395472. Show all entries for this paper.

Fortin2000 J. F. Fortin, R. Cantin, M. G. Bergeron, and M. J. Tremblay. Interaction between Virion-Bound Host Intercellular Adhesion Molecule-1 and the High-Affinity State of Lymphocyte Function-Associated Antigen-1 on Target Cells Renders R5 and X4 Isolates of Human Immunodeficiency Virus Type 1 More Refractory to Neutralization. Virology, 268:493-503, 2000. PubMed ID: 10704357. Show all entries for this paper.

Garcia2006 Julian Garcia, Pascal Dumy, Osnat Rosen, and Jacob Anglister. Stabilization of the Biologically Active Conformation of the Principal Neutralizing Determinant of HIV-1(IIIB) Containing a cis-Proline Surrogate: 1H NMR and Molecular Modeling Study. Biochemistry, 45(13):4284-4294, 4 Apr 2006. PubMed ID: 16566603. Show all entries for this paper.

Harada2004 Shinji Harada, Keisuke Yusa, and Yosuke Maeda. Heterogeneity of Envelope Molecules Shown by Different Sensitivities to anti-V3 Neutralizing Antibody and CXCR4 Antagonist Regulates the Formation of Multiple-Site Binding of HIV-1. Microbiol. Immunol., 48(4):357-365, 2004. PubMed ID: 15107547. Show all entries for this paper.

Harada2008 Shinji Harada, Kazuaki Monde, Yuetsu Tanaka, Tetsuya Kimura, Yosuke Maeda, and Keisuke Yusa. Neutralizing Antibodies Decrease the Envelope Fluidity of HIV-1. Virology, 370(1):142-150, 5 Jan 2008. PubMed ID: 17900650. Show all entries for this paper.

Huang1997 X. Huang, J. J. Barchi, Jr., F. D. Lung, P. P. Roller, P. L. Nara, J. Muschik, and R. R. Garrity. Glycosylation Affects Both the Three-Dimensional Structure and Antibody Binding Properties of the HIV-1IIIB GP120 Peptide. Biochemistry, 36:10846-10856, 1997. Glycosylated analogues of the V3 loop of gp120 were studied using NMR and circular dichroism spectroscopies, and by AB binding properties to MAb 0.5 $\beta$. A 24-residue peptide from the HIV-1 IIIB isolate (residues 308-331) designated RP135, was glycosylated with both N- and O- linked sugars. PubMed ID: 9312273. Show all entries for this paper.

Huang2005 Chih-chin Huang, Min Tang, Mei-Yun Zhang, Shahzad Majeed, Elizabeth Montabana, Robyn L. Stanfield, Dimiter S. Dimitrov, Bette Korber, Joseph Sodroski, Ian A. Wilson, Richard Wyatt, and Peter D. Kwong. Structure of a V3-Containing HIV-1 gp120 Core. Science, 310(5750):1025-1028, 11 Nov 2005. PubMed ID: 16284180. Show all entries for this paper.

Jagodzinski1996 P. P. Jagodzinski, J. Wustner, D. Kmieciak, T. J. Wasik, A. Fertala, A. L. Sieron, M. Takahashi, T. Tsuji, T. Mimura, M. S. Fung, M. K. Gorny, M. Kloczewiak, Y. Kaneko, and D. Kozbor. Role of the V2, V3, and CD4-Binding Domains of GP120 in Curdlan Sulfate Neutralization Sensitivity of HIV-1 during Infection of T Lymphocytes. Virology, 226:217-227, 1996. PubMed ID: 8955041. Show all entries for this paper.

Jagodzinski2000 P. P. Jagodzinski and W. H. Trzeciak. Application of monoclonal antibodies to monitor the synthesis of a glycoprotein core of envelope glycoproteins of human immunodeficiency virus (HIV-1). Biomed. Pharmacother., 54:50-3, 2000. PubMed ID: 10721463. Show all entries for this paper.

Jeffs1996 S. A. Jeffs, J. McKeating, S. Lewis, H. Craft, D. Biram, P. E. Stephens, and R. L. Brady. Antigenicity of truncated forms of the human immunodeficiency virus type 1 envelope glycoprotein. J. Gen. Virol., 77:1403-1410, 1996. PubMed ID: 8757980. Show all entries for this paper.

Kawai2003 Masahiro Kawai, Lianying He, Takeshi Kawamura, Shinya Omoto, Yoichi R. Fujii, and Noriko Okada. Chimeric Human/Murine Monoclonal IgM Antibodies to HIV-1 Nef Antigen Expressed on Chronically Infected Cells. Microbiol. Immunol., 47(3):247-253, 2003. PubMed ID: 12725296. Show all entries for this paper.

Klasse1993b P. Klasse, J. A. McKeating, M. Schutten, M. S. Reitz, Jr., and M. Robert-Guroff. An Immune-Selected Point Mutation in the Transmembrane Protein of Human Immunodeficiency Virus Type 1 (HXB2-Env:Ala 582(--> Thr)) Decreases Viral Neutralization by Monoclonal Antibodies to the CD4-Binding Site. Virology, 196:332-337, 1993. PubMed ID: 8356803. Show all entries for this paper.

Maeda1992 Y. Maeda, S. Matsushita, T. Hattori, T. Murakami, and K. Takatsuki. Changes in the Reactivity and Neutralizing Activity of a Type-Specific Neutralizing Monoclonal Antibody Induced by Interaction of Soluble CD4 with gp120. AIDS Res. Hum. Retroviruses, 8:2049-2054, 1992. PubMed ID: 1493053. Show all entries for this paper.

Matsushita1992 S. Matsushita, H. Maeda, K. Kimachi, Y. Eda, Y. Maeda, T. Murakami, S. Tokiyoshi, and K. Takatsuki. Characterization of a Mouse/Human Chimeric Monoclonal Antibody (C-beta-1) to a Principal Neutralizing Domain of the Human Immunodeficiency Virus Type 1 Envelope Protein. AIDS Res. Hum. Retroviruses, 8:1107-1115, 1992. PubMed ID: 1380258. Show all entries for this paper.

McDougal1996 J. S. McDougal, M. S. Kennedy, S. L. Orloff, J. K. A. Nicholson, and T. J. Spira. Mechanisms of Human Immunodeficiency Virus Type 1 (HIV-1) Neutralization: Irreversible Inactivation of Infectivity by Anti-HIV-1 Antibody. J. Virol., 70:5236-5245, 1996. Studies of polyclonal sera autologous virus inactivation indicates that in individuals over time, viral populations emerge that are resistant to inactivating effects of earlier sera. PubMed ID: 8764033. Show all entries for this paper.

McKeating1992a J. A. McKeating, J. Cordell, C. J. Dean, and P. Balfe. Synergistic Interaction between Ligands Binding to the CD4 Binding Site and V3 Domain of Human Immunodeficiency Virus Type I gp120. Virology, 191:732-742, 1992. PubMed ID: 1280382. Show all entries for this paper.

Moore1993c J. P. Moore, M. Thali, B. A. Jameson, F. Vignaux, G. K. Lewis, S.-W. Poon, M. S. Fung, P. J. Durda, L. Akerblom, B. Wahren, D. D. Ho, Q. J. Sattentau, and J. Sodroski. Immunochemical Analysis of the gp120 Surface Glycoprotein of Human Immunodeficiency Virus Type 1: Probing the Structure of the C4 and V4 Domains and the Interaction of the C4 Domain with the V3 Loop. J. Virol., 73:4785-4796, 1993. General observations: C4 and V3 MAbs are sensitive to the way the epitopes are presented, and this sensitivity cannot be correlated to peptide binding. Some V3-C4 domain interaction was indicated based on mutation and interference studies. PubMed ID: 7687303. Show all entries for this paper.

Mor2009 Amit Mor, Eugenia Segal, Brenda Mester, Boris Arshava, Osnat Rosen, Fa-Xiang Ding, Joseph Russo, Amnon Dafni, Fabian Schvartzman, Tali Scherf, Fred Naider, and Jacob Anglister. Mimicking the Structure of the V3 Epitope Bound to HIV-1 Neutralizing Antibodies. Biochemistry, 48(15):3288-3303, 21 Apr 2009. PubMed ID: 19281264. Show all entries for this paper.

Nara1990 P. L. Nara, L. Smit, N. Dunlop, W. Hatch, M. Merges, D. Waters, J. Kelliher, R. C. Gallo, P. J. Fischinger, and J. Goudsmit. Emergence of viruses resistant to neutralization by V3-specific antibodies in experimental human immunodeficiency virus type 1 IIIB infection of chimpanzees. J. Virol., 64:3779-3791, 1990. PubMed ID: 2370681. Show all entries for this paper.

Okada1994 T. Okada, B. K. Patterson, P. A. Otto, and M. E. Gurney. HIV Type 1 Infection of CD4+ T-Cells Depends Critically on Basic Amino Acid Residues in the V3 Domain of Envelope Glycoprotein 120. AIDS Res. Hum. Retroviruses, 10:803-811, 1994. PubMed ID: 7986586. Show all entries for this paper.

Okada2005 Noriko Okada, Shuping Yin, Suzuka Asai, Noriaki Kimbara, Natsuki Dohi, Masato Hosokawa, Xiaoshan Wu, and Hidechika Okada. Human IgM Monoclonal Antibodies Reactive with HIV-1-Infected Cells Generated Using a Trans-Chromosome Mouse. Microbiol. Immunol., 49(5):447-459, 2005. PubMed ID: 15905607. Show all entries for this paper.

Reitz1988 M. S. Reitz, Jr., C. Wilson, C. Naugle, and M. Robert-Guroff. Generation of a Neutralization-Resistant Variant of HIV-1 Is Due to Selection for a Point Mutation in the Envelope Gene. Cell, 54:57-63, 1988. Growth of HXB2 in the constant presence of a neutralizing antiserum yielded a viral population resistant to the same serum. gp41 mutation 582 (Ala to Thr) conferred the resistant phenotype. PubMed ID: 2838179. Show all entries for this paper.

Rosen2005 Osnat Rosen, Jordan Chill, Michal Sharon, Naama Kessler, Brenda Mester, Susan Zolla-Pazner, and Jacob Anglister. Induced Fit in HIV-Neutralizing Antibody Complexes: Evidence for Alternative Conformations of the gp120 V3 Loop and the Molecular Basis for Broad Neutralization. Biochemistry, 44(19):7250-7158, 17 May 2005. PubMed ID: 15882063. Show all entries for this paper.

Sirois2007 Suzanne Sirois, Mohamed Touaibia, Kuo-Chen Chou, and Rene Roy. Glycosylation of HIV-1 gp120 V3 Loop: Towards the Rational Design of a Synthetic Carbohydrate Vaccine. Curr. Med. Chem., 14(30):3232-3242, 2007. PubMed ID: 18220757. Show all entries for this paper.

Skinner1988 M. A. Skinner, R. Ting, A. J. Langlois, K. J. Weinhold, H. K. Lyerly, K. Javaherian, and T. J. Matthews. Characteristics of a Neutralizing Monoclonal Antibody to the HIV Envelope Glycoprotein. AIDS Res. Hum. Retroviruses, 4:187-197, 1988. PubMed ID: 2456088. Show all entries for this paper.

Skinner1988a M. A. Skinner, A. J. Langlois, C. B. McDanal, J. S. McDougal, D. P. Bolognesi, and T. J. Matthews. Neutralizing Antibodies to an Immunodominant Envelope Sequence Do Not Prevent gp120 Binding to CD4. J. Virol., 62:4195-4200, 1988. This report was an early suggestion that there are at least two classes of biologically active antibodies to HIV: one class is isolate restricted, primarily directed to a hypervariable loop structure of gp120 and not involved in CD4 binding; the second class is directed at more conserved structures that may directly block CD4 binding. PubMed ID: 2845130. Show all entries for this paper.

Sperlagh1993 M. Sperlagh, K. Stefano, F. Gonzalez-Scarano, S. Liang, J. Hoxie, H. Maruyama, M. Prewett, S. Matsushito, and D. Herlyn. Monoclonal Anti-Idiotype Antibodies That Mimic the Epitope on gp120 Defined by the Anti-HIV-1 Monoclonal Antibody 0.5beta. AIDS, 7:1553-1559, 1993. PubMed ID: 7506914. Show all entries for this paper.

Thali1994 M. Thali, M. Charles, C. Furman, L. Cavacini, M. Posner, J. Robinson, and J. Sodroski. Resistance to Neutralization by Broadly Reactive Antibodies to the Human Immunodeficiency Virus Type 1 gp120 Glycoprotein Conferred by a gp41 Amino Acid Change. J. Virol., 68:674-680, 1994. A T->A amino acid substitution at position 582 of gp41 conferred resistance to neutralization to 30\% of HIV positive sera (Wilson et al. J Virol 64:3240-48 (1990)). Monoclonal antibodies that bound to the CD4 binding site were unable to neutralize this virus, but the mutation did not reduce the neutralizing capacity of a V2 region MAb G3-4, V3 region MAbs, or gp41 neutralizing MAb 2F5. PubMed ID: 7507184. Show all entries for this paper.

Tugarinov1999 Vitali Tugarinov, Anat Zvi, Rina Levy, and Jacob Anglister. A cis Proline Turn Linking Two Beta-Hairpin Strands in the Solution Structure of an Antibody-Bound HIV-1 IIIB V3 Peptide. Nat. Struct. Biol., 6(4):331-335, Apr 1999. PubMed ID: 10201400. Show all entries for this paper.

Tugarinov2000 V. Tugarinov, A. Zvi, R. Levy, Y. Hayek, S. Matsushita, and J. Anglister. NMR Structure of an Anti-gp120 Antibody Complex with a V3 Peptide Reveals a Surface Important for Co-Receptor Binding. Structure, 8:385-395, 2000. PubMed ID: 10801487. Show all entries for this paper.

Veronese1993 F. di Marzo Veronese, M. S. Reitz, Jr., G. Gupta, M. Robert-Guroff, C. Boyer-Thompson, A. Louie, R. C. Gallo, and P. Lusso. Loss of a Neutralizing Epitope by a Spontaneous Point Mutation in the V3 Loop of HIV-1 Isolated from an Infected Laboratory Worker. J. Biol. Chem., 268:25894-25901, 1993. The MAb M77 cannot neutralize a virus isolated from a IIIB infected lab-worker that has a single point mutation in the defined linear epitope. M77 cannot bind to the mutant native gp120, but can bind to a peptide that carries the substitution. PubMed ID: 7503990. Show all entries for this paper.

Vijh-Warrier1996 Sujata Vijh-Warrier, Abraham Pinter, William J. Honnen, and Shermaine A. Tilley. Synergistic Neutralization of Human Immunodeficiency Virus Type 1 by a Chimpanzee Monoclonal Antibody against the V2 Domain of gp120 in Combination with Monoclonal Antibodies against the V3 Loop and the CD4-Binding Site. J. Virol., 70(7):4466-4473, Jul 1996. PubMed ID: 8676471. Show all entries for this paper.

Watkins1993 B. A. Watkins, M. S. Reitz, Jr., C. A. Wilson, K. Aldrich, A. E. Davis, and M. Robert-Guroff. Immune escape by human immunodeficiency virus type 1 from neutralizing antibodies: evidence for multiple pathways. J. Virol., 67:7493-7500, 1993. A neutralization resistance point mutation (HXB2 A281V) was studied using a variety of MAbs, and it was shown that this substitution affects a different epitope than a previously characterized neutralization escape mutant (A582T) (Reitz 1988, Wilson 1990). PubMed ID: 7693973. Show all entries for this paper.

Wyatt1997 R. Wyatt, E. Desjardin, U. Olshevsky, C. Nixon, J. Binley, V. Olshevsky, and J. Sodroski. Analysis of the Interaction of the Human Immunodeficiency Virus Type 1 gp120 Envelope Glycoprotein with the gp41 Transmembrane Glycoprotein. J. Virol., 71:9722-9731, 1997. This study characterized the binding of gp120 and gp41 by comparing Ab reactivity to soluble gp120 and to a soluble complex of gp120 and gp41 called sgp140. The occlusion of gp120 epitopes in the sgp140 complex provides a guide to the gp120 domains that interact with gp41, localizing them in C1 and C5 of gp120. Mutations that disrupt the binding of the occluded antibodies do not influence NAb binding or CD4 binding, thus if the gp41 binding domain is deleted, the immunologically desirable features of gp120 for vaccine design are still intact. PubMed ID: 9371638. Show all entries for this paper.

Zvi1995 A. Zvi, I. Kustanovich, Y. Hayek, S. Matsushita, and J. Anglister. The Principal Neutralizing Determinant of HIV-1 Located in V3 of gp120 Forms a 12-Residue Loop by Internal Hydrophobic Interactions. FEBS Lett., 368:267-270, 1995. PubMed ID: 7543061. Show all entries for this paper.

Zvi1995a A. Zvi, I. Kustanovich, D. Feigelson, R. Levy, M. Eisenstein, S. Matsushita, P. Richalet-Secordel, M. H. Regenmortel, and J. Anglister. NMR Mapping of the Antigenic Determinant Recognized by an Anti-gp120, Human Immunodeficiency Virus Neutralizing Antibody. Eur. J. Biochem., 229:178-187, 1995. PubMed ID: 7538073. Show all entries for this paper.

Zvi1997 A. Zvi, D. J. Feigelson, Y. Hayek, and J. Anglister. Conformation of the principal neutralizing determinant of human immunodeficiency virus type 1 in complex with an anti-gp120 virus neutralizing antibody studied by two-dimensional nuclear magnetic resonance difference spectroscopy. Biochemistry, 36:8619-27, 1997. PubMed ID: 9214308. Show all entries for this paper.

Zvi2000 A. Zvi, V. Tugarinov, G. A. Faiman, A. Horovitz, and J. Anglister. A Model of a gp120 V3 Peptide in Complex with an HIV-Neutralizing Antibody Based on NMR and Mutant Cycle-Derived Constraints. Eur. J. Biochem., 267:767-779, 2000. PubMed ID: 10651813. Show all entries for this paper.


Displaying record number 509

Download this epitope record as JSON.

MAb ID 902 (H902)
HXB2 Location gp160(313-324)
DNA(7161..7196)
gp160 Epitope Map
Author Location gp120( IIIB)
Research Contact Bruce Chesebro, Rocky Mountain National Laboratory, Montana
Epitope PGRAFVTIGKIG Epitope Alignment
PGRAFVTIGKIG epitope logo
Ab Type gp120 V3 // V3 glycan (V3g)
Neutralizing L
Species (Isotype) mouse(IgG1κ)
Patient  
Immunogen vaccine
Keywords antibody binding site, neutralization, rate of progression

Vaccine Details

Vaccine type vaccinia
Vaccine strain B clade IIIB
Vaccine component gp160

Notes

Showing 8 of 8 notes.

References

Showing 9 of 9 references.

Chesebro1988 B. Chesebro and K. Wehrly. Development of a Sensitive Quantitative Focal Assay for Human Immunodeficiency Virus Infectivity. J. Virol., 62:3779-3788, 1988. PubMed ID: 3047430. Show all entries for this paper.

Laman1993 J. D. Laman, M. M. Schellekens, G. K. Lewis, J. P. Moore, T. J. Matthews, J. P. M. Langedijk, R. H. Meloen, W. J. A. Boersma, and E. Claassen. A Hidden Region in the Third Variable Domain of HIV-1 IIIB gp120 Identified by a Monoclonal Antibody. AIDS Res. Hum. Retroviruses, 9:605-612, 1993. A peptide (FVTIGKIGNMRQAHC) induced MAb binds to the carboxy-terminal flank of the V3-loop, but the epitope is only exposed on gp120 when it is treated with SDS-DTT. PubMed ID: 8369165. Show all entries for this paper.

Broder1994 C.C. Broder, P.L. Earl, D. Long, S.T. Abedon, B. Moss, and R.W. Doms. Antigenic implications of human immunodeficiency virus type 1 envelope quaternary structure: Oligomer-specific and -sensitive monoclonal antibodies. Proc. Natl. Acad. Sci. U.S.A., 91:11699-11703, 1994. 35 anti-gp41 and 27 anti-gp120 murine MAbs generated by immunization with oligomeric HIV-1 IIIB envelope were studied. These MAbs tended to react with conformational epitopes. 21 of the anti-gp41 MAbs reacted preferentially with oligomeric env, while only 1 of the anti-gp120 MAbs reacted more strongly with the oligomer, and 14 of the anti-gp120 preferentially recognized monomeric env. PubMed ID: 7972127. Show all entries for this paper.

Earl1994 P. L. Earl, C. C. Broder, D. Long, S. A. Lee, J. Peterson, S. Chakrabarti, R. W. Doms, and B. Moss. Native oligomeric human immunodeficiency virus type 1 Envelope glycoprotein elicits diverse monoclonal antibody reactivities. J. Virol., 68:3015-3026, 1994. In a study of the repertoire of response to oligomeric versus monomeric Env protein, 138 murine MAbs were generated in response to an immunogen that was a gp120/bp41 oligomeric molecule that was not cleaved due to a mutation in the cleavage site. The oligomeric molecule was found to elicit a response that was very different than the monomer. Most MAbs were conformational, many were to gp41 or if in gp120, to the CD4 BS. Few MAbs to linear V3 epitopes were produced in response to oligomeric protein, though this was a common specificity in response to immunization with gp120 monomeric protein. PubMed ID: 7512157. Show all entries for this paper.

Sakaida1997 H. Sakaida, T. Murakami, S. Kawamata, T. Hattori, and T. Uchiyama. V3 Loop of Human Immunodeficiency Virus Type 1 Suppresses Interleukin 2-Induced T Cell Growth. AIDS Res. Hum. Retroviruses, 13:151-159, 1997. See comments in AIDS Res Hum Retroviruses 13:633 (1997). PubMed ID: 9007200. Show all entries for this paper.

Ling2004 Hong Ling, Peng Xiao, Osamu Usami, and Toshio Hattori. Thrombin Activates Envelope Glycoproteins of HIV Type 1 and Enhances Fusion. Microbes Infect., 6(5):414-420, Apr 2004. PubMed ID: 15109955. Show all entries for this paper.

Usami2005 Osamu Usami, Peng Xiao, Hong Ling, Yi Liu, Tadashi Nakasone, and Toshio Hattori. Properties of Anti-gp41 Core Structure Antibodies, Which Compete with Sera of HIV-1-Infected Patients. Microbes Infect., 7(4):650-657, Apr 2005. PubMed ID: 15823513. Show all entries for this paper.

Bosch2009 Valerie Bosch, Tanya Pfeiffer, Gerard Devitt, Ina Allespach, Thomas Ebensen, Vanessa Emerson, Carlos A. Guzman, and Oliver T. Keppler. HIV Pseudovirion Vaccine Exposing Env ``fusion intermediates''---Response to Immunisation in Human CD4/CCR5-Transgenic Rats. Vaccine, 27(16):2202-2212, 6 Apr 2009. PubMed ID: 19428834. Show all entries for this paper.

Mizukami1988 Tamio Mizukami, Thomas R. Fuerst, Edward A. Berger, and Bernard Moss. Binding Region for Human Immunodeficiency Virus (HIV) and Epitopes for HIV-Blocking Monoclonal Antibodies of the CD4 Molecule Defined by Site-Directed Mutagenesis. Proc. Natl. Acad. Sci. U.S.A., 85(23):9273-9277, Dec 1988. PubMed ID: 2461565. Show all entries for this paper.


Displaying record number 612

Download this epitope record as JSON.

MAb ID D20
HXB2 Location Env Env Epitope Map
Author Location gp120( IIIB)
Research Contact P. Earl, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD
Epitope
Ab Type gp120 CD4BS
Neutralizing  
Species (Isotype) mouse(IgG)
Patient  
Immunogen vaccine
Keywords antibody binding site, antibody generation

Vaccine Details

Vaccine type vaccinia
Vaccine strain B clade IIIB
Vaccine component oligomeric gp140

Notes

Showing 6 of 6 notes.

References

Showing 6 of 6 references.

Isolation Paper
Earl1994 P. L. Earl, C. C. Broder, D. Long, S. A. Lee, J. Peterson, S. Chakrabarti, R. W. Doms, and B. Moss. Native oligomeric human immunodeficiency virus type 1 Envelope glycoprotein elicits diverse monoclonal antibody reactivities. J. Virol., 68:3015-3026, 1994. In a study of the repertoire of response to oligomeric versus monomeric Env protein, 138 murine MAbs were generated in response to an immunogen that was a gp120/bp41 oligomeric molecule that was not cleaved due to a mutation in the cleavage site. The oligomeric molecule was found to elicit a response that was very different than the monomer. Most MAbs were conformational, many were to gp41 or if in gp120, to the CD4 BS. Few MAbs to linear V3 epitopes were produced in response to oligomeric protein, though this was a common specificity in response to immunization with gp120 monomeric protein. PubMed ID: 7512157. Show all entries for this paper.

Broder1994 C.C. Broder, P.L. Earl, D. Long, S.T. Abedon, B. Moss, and R.W. Doms. Antigenic implications of human immunodeficiency virus type 1 envelope quaternary structure: Oligomer-specific and -sensitive monoclonal antibodies. Proc. Natl. Acad. Sci. U.S.A., 91:11699-11703, 1994. 35 anti-gp41 and 27 anti-gp120 murine MAbs generated by immunization with oligomeric HIV-1 IIIB envelope were studied. These MAbs tended to react with conformational epitopes. 21 of the anti-gp41 MAbs reacted preferentially with oligomeric env, while only 1 of the anti-gp120 MAbs reacted more strongly with the oligomer, and 14 of the anti-gp120 preferentially recognized monomeric env. PubMed ID: 7972127. Show all entries for this paper.

Earl1997 P. L. Earl, C. C. Broder, R. W. Doms, and B. Moss. Epitope map of human immunodeficiency virus type 1 gp41 derived from 47 monoclonal antibodies produced by immunization with oligomeric envelope protein. J. Virol., 71:2674-84, 1997. PubMed ID: 9060620. Show all entries for this paper.

Otteken1996 A. Otteken, P. L. Earl, and B. Moss. Folding, assembly, and intracellular trafficking of the human immunodeficiency virus type 1 Envelope glycoprotein analyzed with monoclonal antibodies recognizing maturational intermediates. J. Virol., 70:3407-15, 1996. PubMed ID: 8648672. Show all entries for this paper.

Richardson1996 T. M. Richardson, Jr., B. L. Stryjewski, C. C. Broder, J. A. Hoxie, J. R. Mascola, P. L. Earl, and R. W. Doms. Humoral response to oligomeric human immunodeficiency virus type 1 envelope protein. J. Virol., 70:753-62, 1996. An Env antigen capture enzyme-linked immunosorbent assay using a soluble, oligomeric form of HIV-1IIIB Env (gp140) that contains gp120 and the gp41 ectodomain was developed. The gp140, captured by various monoclonal antibodies (MAbs), retained its native oligomeric structure: it bound CD4 and was recognized by MAbs to conformational epitopes in gp120 and gp41, including oligomer-specific epitopes in gp41. PubMed ID: 8551612. Show all entries for this paper.

Sugiura1999 W. Sugiura, C. C. Broder, B. Moss, and P. L. Earl. Characterization of conformation-dependent anti-gp120 murine monoclonal antibodies produced by immunization with monomeric and oligomeric human immunodeficiency virus type 1 envelope proteins. Virology, 254:257-67, 1999. PubMed ID: 9986792. Show all entries for this paper.


Displaying record number 864

Download this epitope record as JSON.

MAb ID T4
HXB2 Location Env Env Epitope Map
Author Location gp41( IIIB)
Epitope
Ab Type  
Neutralizing L
Species (Isotype) mouse(IgG)
Patient  
Immunogen vaccine
Keywords antibody binding site, antibody generation, antibody interactions, vaccine antigen design

Vaccine Details

Vaccine type vaccinia
Vaccine strain B clade IIIB
Vaccine component oligomeric gp140

Notes

Showing 9 of 9 notes.

References

Showing 10 of 10 references.

Isolation Paper
Earl1994 P. L. Earl, C. C. Broder, D. Long, S. A. Lee, J. Peterson, S. Chakrabarti, R. W. Doms, and B. Moss. Native oligomeric human immunodeficiency virus type 1 Envelope glycoprotein elicits diverse monoclonal antibody reactivities. J. Virol., 68:3015-3026, 1994. In a study of the repertoire of response to oligomeric versus monomeric Env protein, 138 murine MAbs were generated in response to an immunogen that was a gp120/bp41 oligomeric molecule that was not cleaved due to a mutation in the cleavage site. The oligomeric molecule was found to elicit a response that was very different than the monomer. Most MAbs were conformational, many were to gp41 or if in gp120, to the CD4 BS. Few MAbs to linear V3 epitopes were produced in response to oligomeric protein, though this was a common specificity in response to immunization with gp120 monomeric protein. PubMed ID: 7512157. Show all entries for this paper.

Broder1994 C.C. Broder, P.L. Earl, D. Long, S.T. Abedon, B. Moss, and R.W. Doms. Antigenic implications of human immunodeficiency virus type 1 envelope quaternary structure: Oligomer-specific and -sensitive monoclonal antibodies. Proc. Natl. Acad. Sci. U.S.A., 91:11699-11703, 1994. 35 anti-gp41 and 27 anti-gp120 murine MAbs generated by immunization with oligomeric HIV-1 IIIB envelope were studied. These MAbs tended to react with conformational epitopes. 21 of the anti-gp41 MAbs reacted preferentially with oligomeric env, while only 1 of the anti-gp120 MAbs reacted more strongly with the oligomer, and 14 of the anti-gp120 preferentially recognized monomeric env. PubMed ID: 7972127. Show all entries for this paper.

Richardson1996 T. M. Richardson, Jr., B. L. Stryjewski, C. C. Broder, J. A. Hoxie, J. R. Mascola, P. L. Earl, and R. W. Doms. Humoral response to oligomeric human immunodeficiency virus type 1 envelope protein. J. Virol., 70:753-62, 1996. An Env antigen capture enzyme-linked immunosorbent assay using a soluble, oligomeric form of HIV-1IIIB Env (gp140) that contains gp120 and the gp41 ectodomain was developed. The gp140, captured by various monoclonal antibodies (MAbs), retained its native oligomeric structure: it bound CD4 and was recognized by MAbs to conformational epitopes in gp120 and gp41, including oligomer-specific epitopes in gp41. PubMed ID: 8551612. Show all entries for this paper.

Weissenhorn1996 W. Weissenhorn, S. A. Wharton, L. J. Calder, P. L. Earl, B. Moss, E. Aliprandis, J. J. Skehel, and D. C. Wiley. The Ectodomain of HIV-1 Env Subunit gp41 Forms a Soluble, alpha-Helical, Rod-Like Oligomer in the Absence of gp120 and the N-Terminal Fusion Peptide. EMBO J., 15:1507-1514, 1996. PubMed ID: 8612573. Show all entries for this paper.

Otteken1996 A. Otteken, P. L. Earl, and B. Moss. Folding, assembly, and intracellular trafficking of the human immunodeficiency virus type 1 Envelope glycoprotein analyzed with monoclonal antibodies recognizing maturational intermediates. J. Virol., 70:3407-15, 1996. PubMed ID: 8648672. Show all entries for this paper.

Earl1997 P. L. Earl, C. C. Broder, R. W. Doms, and B. Moss. Epitope map of human immunodeficiency virus type 1 gp41 derived from 47 monoclonal antibodies produced by immunization with oligomeric envelope protein. J. Virol., 71:2674-84, 1997. PubMed ID: 9060620. Show all entries for this paper.

Binley2000 J. Binley, R. Sanders, B. Clas, N. Schuelke, A. Master, Y. Guo, F. Kajumo, D. Anselma, P. Maddon, W. Olson, and J. Moore. A Recombinant Human Immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an intramolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion associated structure. J. Virol., 74:627-43, 1999. PubMed ID: 10623724. Show all entries for this paper.

Stamatatos2000 L. Stamatatos, M. Lim, and C. Cheng-Mayer. Generation and structural analysis of soluble oligomeric gp140 envelope proteins derived from neutralization-resistant and neutralization-susceptible primary HIV type 1 isolates. AIDS Res. Hum. Retroviruses, 16(10):981--94, 1 Jul 2000. PubMed ID: 10890360. Show all entries for this paper.

Yang2000 Xinzhen Yang, Michael Farzan, Richard Wyatt, and Joseph Sodroski. Characterization of Stable, Soluble Trimers Containing Complete Ectodomains of Human Immunodeficiency Virus Type 1 Envelope Glycoproteins. J. Virol., 74(12):5716-5725, Jun 2000. PubMed ID: 10823881. Show all entries for this paper.

Srivastava2002 Indresh K. Srivastava, Leonidas Stamatatos, Harold Legg, Elaine Kan, Anne Fong, Stephen R. Coates, Louisa Leung, Mark Wininger, John J. Donnelly, Jeffrey B. Ulmer, and Susan W. Barnett. Purification and Characterization of Oligomeric Envelope Glycoprotein from a Primary R5 Subtype B Human Immunodeficiency Virus. J. Virol., 76(6):2835-2847, Mar 2002. URL: http://jvi.asm.org/cgi/content/full/76/6/2835. PubMed ID: 11861851. Show all entries for this paper.


Displaying record number 865

Download this epitope record as JSON.

MAb ID D12
HXB2 Location Env Env Epitope Map
Author Location gp41( IIIB)
Research Contact Patricia Earl and Christopher Broder, NIH
Epitope
Ab Type  
Neutralizing L
Species (Isotype) mouse(IgG)
Patient  
Immunogen vaccine
Keywords antibody binding site, antibody generation, antibody interactions, vaccine antigen design

Vaccine Details

Vaccine type vaccinia
Vaccine strain B clade IIIB
Vaccine component oligomeric gp140

Notes

Showing 7 of 7 notes.

References

Showing 7 of 7 references.

Isolation Paper
Earl1994 P. L. Earl, C. C. Broder, D. Long, S. A. Lee, J. Peterson, S. Chakrabarti, R. W. Doms, and B. Moss. Native oligomeric human immunodeficiency virus type 1 Envelope glycoprotein elicits diverse monoclonal antibody reactivities. J. Virol., 68:3015-3026, 1994. In a study of the repertoire of response to oligomeric versus monomeric Env protein, 138 murine MAbs were generated in response to an immunogen that was a gp120/bp41 oligomeric molecule that was not cleaved due to a mutation in the cleavage site. The oligomeric molecule was found to elicit a response that was very different than the monomer. Most MAbs were conformational, many were to gp41 or if in gp120, to the CD4 BS. Few MAbs to linear V3 epitopes were produced in response to oligomeric protein, though this was a common specificity in response to immunization with gp120 monomeric protein. PubMed ID: 7512157. Show all entries for this paper.

Broder1994 C.C. Broder, P.L. Earl, D. Long, S.T. Abedon, B. Moss, and R.W. Doms. Antigenic implications of human immunodeficiency virus type 1 envelope quaternary structure: Oligomer-specific and -sensitive monoclonal antibodies. Proc. Natl. Acad. Sci. U.S.A., 91:11699-11703, 1994. 35 anti-gp41 and 27 anti-gp120 murine MAbs generated by immunization with oligomeric HIV-1 IIIB envelope were studied. These MAbs tended to react with conformational epitopes. 21 of the anti-gp41 MAbs reacted preferentially with oligomeric env, while only 1 of the anti-gp120 MAbs reacted more strongly with the oligomer, and 14 of the anti-gp120 preferentially recognized monomeric env. PubMed ID: 7972127. Show all entries for this paper.

Richardson1996 T. M. Richardson, Jr., B. L. Stryjewski, C. C. Broder, J. A. Hoxie, J. R. Mascola, P. L. Earl, and R. W. Doms. Humoral response to oligomeric human immunodeficiency virus type 1 envelope protein. J. Virol., 70:753-62, 1996. An Env antigen capture enzyme-linked immunosorbent assay using a soluble, oligomeric form of HIV-1IIIB Env (gp140) that contains gp120 and the gp41 ectodomain was developed. The gp140, captured by various monoclonal antibodies (MAbs), retained its native oligomeric structure: it bound CD4 and was recognized by MAbs to conformational epitopes in gp120 and gp41, including oligomer-specific epitopes in gp41. PubMed ID: 8551612. Show all entries for this paper.

Earl1997 P. L. Earl, C. C. Broder, R. W. Doms, and B. Moss. Epitope map of human immunodeficiency virus type 1 gp41 derived from 47 monoclonal antibodies produced by immunization with oligomeric envelope protein. J. Virol., 71:2674-84, 1997. PubMed ID: 9060620. Show all entries for this paper.

Otteken1996 A. Otteken, P. L. Earl, and B. Moss. Folding, assembly, and intracellular trafficking of the human immunodeficiency virus type 1 Envelope glycoprotein analyzed with monoclonal antibodies recognizing maturational intermediates. J. Virol., 70:3407-15, 1996. PubMed ID: 8648672. Show all entries for this paper.

LaBranche1999 C. C. LaBranche, T. L. Hoffman, J. Romano, B. S. Haggarty, T. G. Edwards, T. J. Matthews, R. W. Doms, and J. A. Hoxie. Determinants of CD4 independence for a human immunodeficiency virus type 1 variant map outside regions required for coreceptor specificity. J. Virol., 73(12):10310--9, Dec 1999. URL: http://jvi.asm.org/cgi/content/full/73/12/10310. PubMed ID: 10559349. Show all entries for this paper.

Yang2000 Xinzhen Yang, Michael Farzan, Richard Wyatt, and Joseph Sodroski. Characterization of Stable, Soluble Trimers Containing Complete Ectodomains of Human Immunodeficiency Virus Type 1 Envelope Glycoproteins. J. Virol., 74(12):5716-5725, Jun 2000. PubMed ID: 10823881. Show all entries for this paper.


Displaying record number 1124

Download this epitope record as JSON.

MAb ID T9
HXB2 Location Env Env Epitope Map
Author Location gp41(gp41 )
Research Contact Patricia Earl and Christopher Broder, NIH
Epitope
Ab Type gp41
Neutralizing  
Species (Isotype) mouse(IgG)
Patient  
Immunogen vaccine
Keywords antibody binding site, antibody generation, variant cross-reactivity

Vaccine Details

Vaccine component oligomeric gp140

Notes

Showing 4 of 4 notes.

References

Showing 3 of 3 references.

Broder1994 C.C. Broder, P.L. Earl, D. Long, S.T. Abedon, B. Moss, and R.W. Doms. Antigenic implications of human immunodeficiency virus type 1 envelope quaternary structure: Oligomer-specific and -sensitive monoclonal antibodies. Proc. Natl. Acad. Sci. U.S.A., 91:11699-11703, 1994. 35 anti-gp41 and 27 anti-gp120 murine MAbs generated by immunization with oligomeric HIV-1 IIIB envelope were studied. These MAbs tended to react with conformational epitopes. 21 of the anti-gp41 MAbs reacted preferentially with oligomeric env, while only 1 of the anti-gp120 MAbs reacted more strongly with the oligomer, and 14 of the anti-gp120 preferentially recognized monomeric env. PubMed ID: 7972127. Show all entries for this paper.

Earl1997 P. L. Earl, C. C. Broder, R. W. Doms, and B. Moss. Epitope map of human immunodeficiency virus type 1 gp41 derived from 47 monoclonal antibodies produced by immunization with oligomeric envelope protein. J. Virol., 71:2674-84, 1997. PubMed ID: 9060620. Show all entries for this paper.

GoldingH2002 Hana Golding, Marina Zaitseva, Eve de Rosny, Lisa R. King, Jody Manischewitz, Igor Sidorov, Miroslaw K. Gorny, Susan Zolla-Pazner, Dimiter S. Dimitrov, and Carol D. Weiss. Dissection of Human Immunodeficiency Virus Type 1 Entry with Neutralizing Antibodies to gp41 Fusion Intermediates. J. Virol., 76(13):6780-6790, Jul 2002. PubMed ID: 12050391. Show all entries for this paper.


Questions or comments? Contact us at immuno@lanl.gov
 
Managed by Triad National Security, LLC for the U.S. Department of Energy’s National Nuclear Security Administration
Copyright © 2022 Triad National Security, LLC | Disclaimer/Privacy

Dept of Health & Human Services Los Alamos National Institutes of Health